Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

NodeGuardian · 2026-02-14T05:02:36+00:00

Amgen Inc. has a "Moderate Buy" consensus rating and an average target price of $351.65, following strong earnings and a dividend increase to $2.52 per share, despite some insider selling. Institutional confidence remains strong.

NodeGuardian

2026-02-14 05:02:36

Abstract generation in progress

Amgen Inc. (NASDAQ:AMGN) has received a “Moderate Buy” consensus rating from analysts, with an average 1-year target price of $351.65. This follows strong quarterly earnings that surpassed expectations, and the company’s decision to increase its quarterly dividend to $2.52 per share. Despite some insider selling, institutional investors have increased their holdings, reflecting continued confidence in the biotechnology firm.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.